Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis

Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and deposits in tissues. Due to the production of amyloidogenic, misfolded LC, AL PCs display peculiar biologic features. The...

Full description

Bibliographic Details
Main Authors: Giovanni Palladini, Paolo Milani, Fabio Malavasi, Giampaolo Merlini
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cells
Subjects:
light-chain amyloidosis
CD38
monoclonal antibody
immunotherapy
Online Access:https://www.mdpi.com/2073-4409/10/3/545

Internet

https://www.mdpi.com/2073-4409/10/3/545

Similar Items